Mineralocorticoid receptor antagonists (MRAs) are a cornerstone of treatment for patients with chronic heart failure and reduced ejection fraction. In international guidelines, these agents have a class I recommendation for use in such patients, on the basis of results from seminal trials that showed reductions in death from any cause,…
The New England Journal of Medicine: Search Results in Cardiology
